SNUS – Let’s make a bet of a 3-month iHub membership. The bet will come into play if and only if Tocosol paclitaxel is approved by the FDA with a non-inferiority label. (I.e., if approved with a superiority label or not approved at all, the bet is off.)
My side of the bet is that the drug will produce less than $200M in cumulative sales during the fist ten quarters on the market.
News 
Market Data 
Discover 
AI
